PDF(Pubmed)
Abstract：
UNASSIGNED: Medication-related osteonecrosis of the Jaw (MRONJ) is a rare complication of the jaws following the administration of antiresorptive or antiangiogenic drugs. This condition poses a major challenge to its management. Its prevention and management need a multidisciplinary collaboration. We described three patients with MRONJ including their presentation, investigations, management protocols, and outcomes. A brief appraisal of the literature on MRONJ was also done.
UNASSIGNED: Medication-related osteonecrosis of the jaw (MRONJ) is a rare complication of the jaws following the administration of antiresorptive or antiangiogenic drugs. This condition poses a major challenge to its management. We present an appraisal of the literature and three cases of MRONJ. An appraisal of 3 patients who presented to the oral and maxillofacial clinic with MRONJ was done. Relevant physical examination findings, radiological images, clinical photographs and follow-up was documented. One patient had multiple myeloma while the other two had metastatic cancer. All had received zoledronic acid before developing MRONJ. One patient was surgically treated and successfully recovered while two were managed conservatively. Patients taking antiresorptive medications are at risk of developing MRONJ. Prevention and management of the condition calls for a multidisciplinary collaboration. Patients taking antiresorptive medications need good education on the risks associated with the medications and how to recognize early signs and symptoms.
UNASSIGNED: Medication-related osteonecrosis of the jaw (MRONJ) is a rare complication of the jaws following the administration of antiresorptive or antiangiogenic drugs. This condition poses a major challenge to its management. We present an appraisal of the literature and three cases of MRONJ. An appraisal of 3 patients who presented to the oral and maxillofacial clinic with MRONJ was done. Relevant physical examination findings, radiological images, clinical photographs and follow-up was documented. One patient had multiple myeloma while the other two had metastatic cancer. All had received zoledronic acid before developing MRONJ. One patient was surgically treated and successfully recovered while two were managed conservatively. Patients taking antiresorptive medications are at risk of developing MRONJ. Prevention and management of the condition calls for a multidisciplinary collaboration. Patients taking antiresorptive medications need good education on the risks associated with the medications and how to recognize early signs and symptoms.
摘要：
■药物相关性颌骨坏死（MRONJ）是一种罕见的颌骨并发症，在服用抗再吸收或抗血管生成药物后。这种情况对其管理构成了重大挑战。它的预防和管理需要多学科合作。我们描述了三名MRONJ患者，包括他们的表现，调查,管理协议，和结果。还对MRONJ的文献进行了简要评估。
■药物相关性颌骨坏死（MRONJ）是一种罕见的颌骨并发症，在服用抗再吸收或抗血管生成药物后。这种情况对其管理构成了重大挑战。我们对文献和三个MRONJ案例进行了评估。对3例因MRONJ就诊于口腔颌面诊所的患者进行了评估。相关体检结果,放射学图像，记录了临床照片和随访情况.一名患者患有多发性骨髓瘤，而另外两名患者患有转移性癌症。在开发MRONJ之前，所有人都接受了唑来膦酸。一名患者接受了手术治疗并成功康复，而两名患者接受了保守治疗。服用抗吸收药物的患者有发生MRONJ的风险。这种疾病的预防和管理需要多学科的合作。服用抗吸收药物的患者需要对与药物相关的风险以及如何识别早期体征和症状进行良好的教育。
■药物相关性颌骨坏死（MRONJ）是一种罕见的颌骨并发症，在服用抗再吸收或抗血管生成药物后。这种情况对其管理构成了重大挑战。我们对文献和三个MRONJ案例进行了评估。对3例因MRONJ就诊于口腔颌面诊所的患者进行了评估。相关体检结果,放射学图像，记录了临床照片和随访情况.一名患者患有多发性骨髓瘤，而另外两名患者患有转移性癌症。在开发MRONJ之前，所有人都接受了唑来膦酸。一名患者接受了手术治疗并成功康复，而两名患者接受了保守治疗。服用抗吸收药物的患者有发生MRONJ的风险。这种疾病的预防和管理需要多学科的合作。服用抗吸收药物的患者需要对与药物相关的风险以及如何识别早期体征和症状进行良好的教育。
